Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-

Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response

Biotechnology investing is a strange corner of the market. A company can own a drug that may even

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ethe

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during i

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Applicati

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the

Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Mo

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Mult

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysi

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström M

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a l

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after t

US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2

US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 e

Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the comp

PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 f

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response o

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management,

Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of

Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declini

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company anno

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednes